Anthony R. Hunter

For the football player, see Tony Hunter (American football).
Anthony Rex Hunter

Anthony Rex Hunter
Born (1943-08-23) 23 August 1943
United Kingdom
Nationality British
Fields Biology
Institutions Salk Institute
University of California, San Diego
Alma mater Felsted, University of Cambridge
Known for kinase
Notable awards Charles S. Mott Prize (1994)
Keio Medical Science Prize (2001)
Wolf Prize in Medicine (2005)
BBVA Foundation Frontiers of Knowledge Award (2014)

Anthony Rex Hunter (born 23 August 1943) is a British-American biologist who is a Professor of Biology at the Salk Institute for Biological Studies and the University of California, San Diego. His research publications list his name as Tony Hunter.[1]

Early life

Anthony R. Hunter was born in 1943 in the United Kingdom and educated at Felsted, prior to Christ's College at Cambridge University.

Career

He received a Ph.D. from the University of Cambridge, in Cambridge, England and held a fellowship at Christ's College in Cambridge (1968–1971) and (1973–1975). From 1971 to 1973, he was a research associate of the Salk Institute for Biological Studies in La Jolla, California. He was then assistant professor 1975–78, associate professor 1978–82, professor 1982 onwards and since 2008 director of the Salk Institute Cancer Center.[2] He also sits on the Selection Committee for Life Science and Medicine which chooses winners of the Shaw Prize.

Research

Dr. Hunter is one of the foremost recognized leaders in the field of cell growth control, growth factor receptors and their signal transduction pathways.

He is well known for discovering that tyrosine phosphorylation is a fundamental mechanism for transmembrane-signal transduction in response to growth factor stimulation and that disregulation of such tyrosine phosphorylation, by activated oncogenic protein tyrosine kinases,[3] is a pivotal mechanism utilized in the malignant transformation of cells. His work is important in signaling pathways and their disorders.

He was a founder of Signal Pharmaceuticals.

He won the Wolf Prize in Medicine in 2005 for "the discovery of protein kinases that phosphorylate tyrosine residues in proteins, critical for the regulation of a wide variety of cellular events, including malignant transformation".[4]

He has been granted along with Charles Sawyers and Joseph Schlessinger with the 2014 BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category for “carving out the path that led to the development of a new class of successful cancer drugs.”

Awards and honors

References

  1. ↑ Bailis, J. M.; Luche, D. D.; Hunter, T.; Forsburg, S. L. (2008). "Minichromosome Maintenance Proteins Interact with Checkpoint and Recombination Proteins to Promote S-Phase Genome Stability". Molecular and Cellular Biology 28 (5): 1724–1738. doi:10.1128/MCB.01717-07. PMC 2258774. PMID 18180284.
  2. ↑ "Tony Hunter FRS". Debretts. Retrieved 18 July 2010.
  3. ↑ Hunter, Tony (May 2008). "Tony Hunter: kinase king. Interview by Ruth Williams". J. Cell Biol. 181 (4): 572–3. doi:10.1083/jcb.1814pi. PMC 2386096. PMID 18490508.
  4. ↑ The Wolf Prize in Medicine at the Wayback Machine (archived February 26, 2009). wolffund.org.il
  5. ↑ "Lists of Royal Society Fellows 1660–2007". London: The Royal Society. Archived from the original on 24 March 2010. Retrieved 18 July 2010.
  6. ↑ The Keio Medical Science Prize. Ms-fund.keio.ac.jp. Retrieved on 2013-10-08.
  7. ↑ Tony Hunter at The Salk Institute. Biology.ucsd.edu. Retrieved on 2013-10-08.
  8. ↑ Tony Hunter Receives Pasarow Award for Cancer Research. Salk Institute for Biological Studies (2011)
  9. ↑ PNAS Member Editor Details. Nrc88.nas.edu. Retrieved on 2013-10-08.

External links

This article is issued from Wikipedia - version of the Monday, April 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.